万邦德：石杉碱甲控释片II/III期临床试验完成首例受试者入组

Core Viewpoint - Wanbangde Pharmaceutical's subsidiary has initiated the first patient enrollment for a pivotal Phase II/III clinical trial of its new drug, Huperzine A controlled-release tablets, aimed at treating mild to moderate Alzheimer's disease dementia, marking it as the largest known Alzheimer's registration study in China [1] Group 1 - The clinical trial employs a multi-center, randomized, double-blind, and double-dummy design, including both placebo and positive drug controls [1] - Huperzine A controlled-release tablets are a self-developed Class 2 new drug by the company, utilizing a biphasic controlled-release technology [1] - The drug aims to achieve rapid onset of action, reduce adverse reactions, and enhance patient medication convenience and long-term adherence [1]